Log in

Relevant bibliographies by topics / High-Dose Methotrexate

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'High-Dose Methotrexate'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'High-Dose Methotrexate.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "High-Dose Methotrexate"

1

Dhanushkodi, Manikandan. "High-dose methotrexate." Indian Journal of Medical and Paediatric Oncology 40, no. 3 (2019): 424. http://dx.doi.org/10.4103/ijmpo.ijmpo_157_19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Hryvkova, L. V. "Anticancer chemotherapy with high-dose methotrexate." Practical oncology 4, no. 1 (2021): 30–38. http://dx.doi.org/10.22141/2663-3272.4.1.2021.229869.

Full text

Abstract:

The literature review is devoted to the use of high doses of methotrexate in oncology. There is a brief historical overview of the use of methotrexate for the treatment of malignant neoplasms; the main mechanism of its cytotoxic effect on tumor cells, the development of resistance to methotrexate, the main indications for the use of high doses of methotrexate and the main side effects of this treatment are considered. The review details the results of using high doses of methotrexate in the treatment of patients with osteosarcoma, non-Hodgkin’s lymphomas, located mainly in the central nervous

APA, Harvard, Vancouver, ISO, and other styles

3

Sullivan, M. P., and I. Ramirez. "Curability of Burkitt's lymphoma with high-dose cyclophosphamide-high-dose methotrexate therapy and intrathecal chemoprophylaxis." Journal of Clinical Oncology 3, no. 5 (1985): 627–36. http://dx.doi.org/10.1200/jco.1985.3.5.627.

Full text

Abstract:

Twenty-four children with Burkitt's lymphoma were treated beginning May 1976 with a regimen alternating high doses of cyclophosphamide and methotrexate in induction and consolidation; only high doses of methotrexate were used in the maintenance phase. Throughout therapy, which was planned for 54 weeks, intrathecal chemoprophylaxis using methotrexate, cytosine arabinoside, and hydrocortisone was coordinated with the high-dose methotrexate infusion therapy to provide CNS chemoprophylaxis that maintained therapeutic methotrexate spinal fluid levels (greater than 10(-6) mol/L) for approximately 60

APA, Harvard, Vancouver, ISO, and other styles

4

Kamen, Barton A. "High-dose Methotrexate: Insecure Rationale." Journal of Pediatric Hematology/Oncology 30, no. 9 (2008): 639–40. http://dx.doi.org/10.1097/mph.0b013e318185f4ee.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Cheok, Meyling H., William E. Evans, and Leo Kager. "High-dose Methotrexate: The Rationale…" Journal of Pediatric Hematology/Oncology 31, no. 3 (2009): 224–25. http://dx.doi.org/10.1097/mph.0b013e318196a2a6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Tortajada-Ituren, Juan José, Juan Pablo Ordovás-Baines, Pilar Llopis-Salvia, and N. Victor Jiménez-Torres. "High-Dose Methotrexate–Doxycycline Interaction." Annals of Pharmacotherapy 33, no. 7-8 (1999): 804–8. http://dx.doi.org/10.1345/aph.18236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Nowak, Thomas J., Aaron H. Lorge, Lisa E. Rein, et al. "Implementation and evaluation of high-dose methotrexate administration guidelines." Journal of Oncology Pharmacy Practice 25, no. 7 (2018): 1675–81. http://dx.doi.org/10.1177/1078155218808866.

Full text

Abstract:

BackgroundHigh-dose methotrexate is used to treat a variety of malignancies. Methotrexate-associated supportive care and the threshold methotrexate level for the discontinuation of supportive care are not consistent among studies. We evaluated the implementation of high-dose methotrexate administration guidelines, which raised the standard threshold methotrexate level for the discontinuation of supportive care from <0.05 to <0.1 µmol.MethodsA single-center, observational analysis of patients receiving high-dose methotrexate from 1 January 2015 to 31 May 2017 was conducted. The primary en

APA, Harvard, Vancouver, ISO, and other styles

8

Tran, Hieu X., and Jon D. Herrington. "Effect of ceftriaxone and cefepime on high-dose methotrexate clearance." Journal of Oncology Pharmacy Practice 22, no. 6 (2016): 801–5. http://dx.doi.org/10.1177/1078155215608524.

Full text

Abstract:

Numerous drug interactions with methotrexate have been identified, which can lead to serious life-threatening effects. Up to 90% of methotrexate is excreted unchanged in the urine with primary excretion dependent on organic anion transport in the renal proximal tubule. The two pathways responsible for methotrexate secretion are organic anion transport 1 and primarily organic anion transport 3. Penicillins undergo tubular secretion via organic anion transport, and cephalosporins are believed to also possess a similar risk when administered with methotrexate; however, there are no human studies

APA, Harvard, Vancouver, ISO, and other styles

9

NAVARRO, M. "Leukocytoclastic Vasculitis After High-Dose Methotrexate." Annals of Internal Medicine 105, no. 3 (1986): 471. http://dx.doi.org/10.7326/0003-4819-105-3-471_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Hendershot, Eleanor, Jocelyn Volpe, Tracey Taylor, et al. "Outpatient High-dose Methotrexate for Osteosarcoma." Journal of Pediatric Hematology/Oncology 41, no. 5 (2019): 394–98. http://dx.doi.org/10.1097/mph.0000000000001238.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "High-Dose Methotrexate"

1

Pinchasik, Dawn. "Predictors of and variability in methotrexate clearance among osteosarcoma patients receiving high-dose therapy." University of Cincinnati / OhioLINK, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1377870526.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Perisoglou, M. "Efficacy and safety of glucarpidase for routine use after high dose methotrexate in patients with bone sarcoma." Thesis, University College London (University of London), 2013. http://discovery.ucl.ac.uk/1416302/.

Full text

Abstract:

Background: High-dose methotrexate (HD-MTX) is an essential component of osteosarcoma treatment. Despite supportive measures MTX-related toxicity results in delays in subsequent chemotherapy administration and potentially reduced treatment efficacy. Alternative rescue regimens utilising glucarpidase in addition to folinic acid may be of benefit in reducing MTX-induced toxicity. Patients and methods: A double blind randomised crossover clinical trial, GLU 1, was designed and activated to determine the efficacy and safety of routine use of glucarpidase after HD-MTX. To establish the frequency of

APA, Harvard, Vancouver, ISO, and other styles

3

Bukowinski, Andrew. "Novel Urinary Biomarkers of Acute Kidney Injury to Detect Toxicity and Predict Clearance in Pediatric Oncology Patients Treated with High Dose Methotrexate." University of Cincinnati / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1427962239.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Fresneau, Brice. "Analyses pronostiques en oncologie pédiatrique : Identification de facteurs de susceptibilité tumorale ou individuelle à l’efficacité et/ou à la toxicité des traitements anticancéreux utilisés chez l’enfant Investigating the Heterogeneity of Alkylating Agents' Efficacy and Toxicity Between Sexes: A Systematic Review and Meta-Analysis of Randomized Trials Comparing Cyclophosphamide and Ifosfamide (MAIAGE Study) Is Alpha-Fetoprotein Decline a Prognostic Factor of Childhood Non-Seminomatous Germ Cell Tumours? Results of the French TGM95 Study New Insight into Severe Ototoxicity after Childhood Cancer. Is there an Impact of Melphalan and Busulfan? A French Childhood Cancer Survivor Study A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated with High-Dose Methotrexate: Data from the OS2006/Sarcoma-09 Trial." Thesis, université Paris-Saclay, 2020. http://www.theses.fr/2020UPASS034.

Full text

Abstract:

Les progrès thérapeutiques en oncologie pédiatrique ont permis une amélioration des taux de survie qui dépassent aujourd’hui 80%. De façon à augmenter les taux de guérison et diminuer les complications et séquelles des traitements, des efforts collaboratifs internationaux ont permis le développement de protocoles thérapeutiques stratifiés sur les facteurs pronostiques majeurs incluant des facteurs biologiques tumoraux issus des analyses moléculaires et notamment génomiques. Cependant, si les traitements utilisés prennent de plus en plus en compte la biologie tumorale, leur adaptation aux facte

APA, Harvard, Vancouver, ISO, and other styles

5

Huang, Kuan-Wei, and 黃冠瑋. "Study of High-dose Methotrexate and Co-medications on Hepatotoxicity for Osteosarcoma Patients at a Medical Center." Thesis, 2019. http://ndltd.ncl.edu.tw/handle/gctwy3.

Full text

Abstract:

碩士<br>國立陽明大學<br>藥理學研究所<br>107<br>Osteosarcoma (OGS) is a cancerous tumor derived from bone, which is most prevalent in children, teenagers and young adults. The current standard treatment of OGS includes surgical resection and chemotherapy. According to 2019 National Comprehensive Cancer Network guideline of bone tumor, MAP, consisted of high dose methotrexate (M), adriamycin (doxorubicin, A) and platinum (cisplatin, P), is the first line therapy. However, severe hepatotoxicity associated with MAP, especially high dose methotrexate (HD-MTX) is more often encountered in Taiwanese than Western p

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "High-Dose Methotrexate"

1

Heijstek, Marloes, Mario Abinun, and Nico Wulffraat. Vaccination in immunocompromised children. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0095.

Full text

Abstract:

Can immunocompromised children be safely and effectively vaccinated? This chapter discusses the recommendations from the European League Against Rheumatism (EULAR) for the immunization of immunocompromised patients. Patients with rheumatic or autoinflammatory diseases treated with high-dose glucocorticoids, high-dose disease-modifying anti-rheumatic drugs (DMARDs), or biologicals are considered immunocompromised. Safe and effective vaccination is crucial in these patients, given their increased risk of infection. Safe vaccination implies that vaccination has no effect on disease activity and h

APA, Harvard, Vancouver, ISO, and other styles

2

Heijstek, Marloes, Mario Abinun, and Nico Wulffraat. Vaccination in immunocompromised children. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199642489.003.0095_update_003.

Full text

Abstract:

Can immunocompromised children be safely and effectively vaccinated? This chapter discusses the recommendations from the European League Against Rheumatism (EULAR) for the immunization of immunocompromised patients. Patients with rheumatic or autoinflammatory diseases treated with high-dose glucocorticoids, high-dose disease-modifying antirheumatic drugs (DMARDs), or biologicals are considered immunocompromised. Safe and effective vaccination is crucial in these patients, given their increased risk of infection. Safe vaccination implies that vaccination has no effect on disease activity and ha

APA, Harvard, Vancouver, ISO, and other styles

3

Harper, Lorraine, and David Jayne. The patient with vasculitis. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0160.

Full text

Abstract:

The goals of treatment in renal vasculitis are to stop vasculitic activity and recover renal function. Subsequent strategies are required to prevent vasculitis returning and to address longer-term co-morbidities caused by tissue damage, drug toxicity, and increased cardiovascular and malignancy risk.Cyclophosphamide and high-dose glucocorticoids remain the standard induction therapy with alternative immunosuppressives, such as azathioprine, to prevent relapse. Plasma exchange improves renal recovery in severe presentations. Refractory disease resulting from a failure of induction or remission

APA, Harvard, Vancouver, ISO, and other styles

4

Jayne, David. Treatment of ANCA-associated vasculitis. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0132.

Full text

Abstract:

The goals of treatment in anti-neutrophil cytoplasm antibody (ANCA) vasculitis are to stop vasculitic activity, to prevent vasculitis returning, and to address longer-term comorbidities caused by tissue damage, drug toxicity, and increased cardiovascular and malignancy risk. Cyclophosphamide and high-dose glucocorticoids remain the standard induction therapy with alternative immunosuppressives, such as methotrexate or azathioprine, to prevent relapse. Refractory disease resulting from a failure of induction or remission maintenance therapy requires alternative agents and rituximab has been par

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "High-Dose Methotrexate"

1

Joerger, Markus. "Primary Central Nervous System Lymphoma: Treatment with High-Dose Methotrexate." In Tumors of the Central Nervous System, Volume 9. Springer Netherlands, 2012. http://dx.doi.org/10.1007/978-94-007-5488-1_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Brenner, Timothy L., and William E. Evans. "Rationale for High-Dose Methotrexate in Childhood Acute Lymphoblastic Leukemia." In Treatment of Acute Leukemias. Humana Press, 2003. https://doi.org/10.1007/978-1-59259-307-1_25.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Momota, Hiroyuki. "Primary CNS Lymphoma: Immunohistochemistry of BCL-6 and Treatment with High-Dose Methotrexate." In Tumors of the Central Nervous System, Volume 9. Springer Netherlands, 2012. http://dx.doi.org/10.1007/978-94-007-5488-1_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Brun, B., J. F. Gimonet, F. Feuilhade, et al. "Dose response relationship in adult osteosarcoma patients treated with Neo-Adjuvant high dose Methotrexate, surgery and adjuvant chemotherapy." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy. Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_84.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Rosen, Gerald. "An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma." In Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Springer US, 1993. http://dx.doi.org/10.1007/978-1-4615-3518-8_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Janka, G. E., K. Winkler, H. Juergens, and U. Goebel. "Early Intensification Therapy in High-Risk Childhood Acute Lymphocytic Leukemia: Lack of Benefit from High-Dose Methotrexate." In Acute Leukemias. Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71213-5_80.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bacci, G., P. Picci, M. Mercuri, et al. "Neo-adjuvant Chemotherapy for Osteosarcoma of the Extremities: The Experience at the Rizzoli Institute in 210 Patients Treated with Two Successively Activated Preoperative Protocols Using High-Dose or Moderate-Dose Methotrexate + Cisplatin or High-Dose Methotrexate + Cisplatin + Doxorubicin." In Progress in Regional Cancer Therapy. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74818-9_28.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Schaison, G., M. F. Auclerc, I. Madelaine, et al. "Central Nervous System Prophylaxis with High Dose Methotrexate. A Pharmacokinetic and Clinical Study: Results of Protocol FRALLE 89." In Haematology and Blood Transfusion / Hämatologie und Bluttransfusion. Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-78350-0_55.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Vokes, Everett E., D. J. Haraf, W. R. Panje, et al. "Cisplatin, 5-Fluorouracil and high dose oral Leucovorin (PFL) with Methotrexate and Piritrexim as Neo-Adjuvant chemotherapy for head and neck cancer." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy. Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Valone, Frank H., Peter S. Wittlinger, Marshall S. Flam, Tom Drakes, Peter D. Eisenberg, and John Hannigan. "A Northern California Oncology Group Randomized Trial of Single Agent 5-FU vs. High-Dose Folinic Acid + 5-FU vs. Methotrexate + 5-FU + Folinic Acid in Patients with Disseminated Measurable Large Bowel Cancer." In Advances in Experimental Medicine and Biology. Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-5607-3_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "High-Dose Methotrexate"

1

Montejano-Hervás, P., I. Reyes-Torres, J. López-Santamaría Donoso, MD Aumente, JR Molina, and MA Rodríguez Villa. "PKP-012 Methotrexate levels in cerebrospinal fluid in children treated with high dose methotrexate." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.440.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Widya, Stefani, and Sunita Dhir. "415 Quality improvement of methotrexate level monitoring in paediatric oncology patients requiring high-dose methotrexate." In Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference, Liverpool, 28–30 June 2022. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2022. http://dx.doi.org/10.1136/archdischild-2022-rcpch.713.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mendoza Acosta, I., P. Tardáguila Molina, Á. Yuste Gutiérrez, et al. "5PSQ-044 Impact of drug interactions in high dose methotrexate elimination." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.361.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Rodríguez Ramallo, H., N. Báez Gutiérrez, C. Alvarez Del Vayo, and B. Fernandez Rubio. "4CPS-281 High dose methotrexate in paediatric osteosarcoma patients: effectiveness and safety." In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.113.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

van den Heuvel, Robert. "High-dose methotrexate or standard interim maintenance in young patients with ALL?" In 64th ASH Annual Meeting, edited by Gert Ossenkoppele. Medicom Medical Publishers, 2023. http://dx.doi.org/10.55788/ed3ec8ea.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bianchi, G., D. Camellino, A. Locaputo, et al. "SAT0228 Step-down methotrexate therapy in rheumatoid arthritis (STEMETRA): a pilot study to assess the safety and the tolerability of high-dose methotrexate." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.2768.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

de la Jara, AM, LM Marangoni-Iglecias, N. Báez-Gutiérrez, A. Sánchez-Martín, C. Pérez-Ramírez, and MR Cantudo Cuenca. "4CPS-061 Impact of pharmacogenetics on the toxicity of high-dose methotrexate in a paediatric population." In 26th EAHP Congress, Hospital pharmacists – changing roles in a changing world, 23–25 March 2022. British Medical Journal Publishing Group, 2022. http://dx.doi.org/10.1136/ejhpharm-2022-eahp.101.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Escolà Rodríguez, A., N. Arranz Pasqual, C. Bastida, et al. "4CPS-014 Comparison of two protocols for the administration of leucovorin rescues after high dose methotrexate infusion of 24 hours." In 27th EAHP Congress, Lisbon, Portugal, 22-23-24 March 2023. British Medical Journal Publishing Group, 2023. http://dx.doi.org/10.1136/ejhpharm-2023-eahp.61.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Palanikumar, Logesh, and Deborah Field. "2971 Methotrexate leukoencephalopathy with clinical and radiological response to high-dose aminophylline and leucovorin: a case report and literature review." In ANZAN Annual Scientific Meeting 2024 Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/bmjno-2024-anzan.21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Zhou, Jihao, Min Zuo, Peng Ke, et al. "Abstract 666: PIM1 and CD79b mutation status impact outcome in primary central nervous system DLBCL after high-dose methotrexate-based chemoimmunotherapy." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-666.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "High-Dose Methotrexate"

1

Bowen, Donnell. Selectivity of Very High Dose Methotrexate in MCF-7 and Normal Cells Using a Priming and Non-Toxic 5-Fluorouracil Dose. Defense Technical Information Center, 1999. http://dx.doi.org/10.21236/ada381717.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Bowen, Donnell. Selectivity of Very High Dose Methotrexate in Mcf-7 and Normal Cells Using a Priming and Non-Toxic 5-Fluorouracil Dose. Defense Technical Information Center, 1998. http://dx.doi.org/10.21236/adb248375.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!